Royalty Report: Drugs, Cancer, Vaccine – Collection: 330896

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Cancer
  • Vaccine
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 330896

License Grant
Licensor hereby grants to Licensee and its Affiliates a worldwide, exclusive (even as to Licensor) license, with the right to sublicense (through one or more multiple tiers) in, to and under the Licensed Patents, Licensed Know How and Licensor Platform, including Modifications, to research, develop, make and have made, to use and have used, to offer to sell, to sell and have sold and to import and export and otherwise exploit Licensed Products in the Field.
License Property
Licensor Platform means Licensor’s proprietary recombinant yeast technology known as “Tarmogen®” technology, and Licensor’s proprietary methods and processes for selecting, engineering, modifying, manufacturing, testing and using Tarmogens.

Tarmogen means Licensors proprietary recombinant yeast technology known as Tarmogen®

Licensed Programs means any and all of (a) the COVID Vaccine Program, (b) the GI-4000 Program, (c) the GI-6100 Program, (d) the GI-6200 Program, (e) the GI-6300 Program, and (f) the Neoepitope Program.

GI-4000 Program means the series of Tarmogen products that express mutated Ras and/or one or more peptides thereof.

GI-6100 Program means the series of Tarmogen products that express human MUC-1 antigen(s).

GI-6200 Program means the series of Tarmogen products that solely express human carcinoembryonic antigen (CEA).

GI-6300 Program means the series of Tarmogen products that express brachyury.

GI-4000 Program means the series of Tarmogen products that express mutated Ras and/or one or more peptides thereof.

GI-6100 Program means the series of Tarmogen products that express human MUC-1 antigen(s).

GI-6200 Program means the series of Tarmogen products that solely express human carcinoembryonic antigen (CEA).

GI-6300 Program means the series of Tarmogen products that express brachyury.

Neoepitope Program means any product engineered using the Licensor Platform to express the protein product of tumor-derived Neoepitope Sequences.

Neoepitope Sequences means unique patient specific protein or peptide sequences that (a) are contained in or on a cancer cell specific to a particular patient who is being treated, (b) differ from a non-malignant cell sequence and is recognizable by the immune system, and (c) are discovered through sequencing of patient tumor cells.

Field of Use
Field of use is for the treatment of various diseases.  Licensee is a immunotherapy and cell therapy company focused on oncology and infectious disease.

IPSCIO Record ID: 256326

License Grant
This amendment is to revise and amend the Agreement to add the Collaboration Compound known as GI-6100 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-3000 as a Drug Candidate under the Agreement.  The patents are also updated.

This amendment adds for the CRADA Research License,  Licensor grants the non-exclusive, worldwide, nontransferable and non-sublicensable license, under the Licensed Intellectual Property, solely as necessary to support research and development activities conducted by the NIH under the CRADA or Cooperative Research and Development Agreement for lntramural-PHS Clinical Research that pertain to certain Collaboration Compounds.

License Property
The candidate compounds
GI-4000 means the series of Tarmogen products that express mutated Ras and/or one or more peptides thereof. GI4014, GI-4015, GI-4016 and GI-4020 arc part of the GI-4000 series and are the subject of [IND No. BB-IND 11653].

GI-6200 means the series of Tarmogen products that solely express human carcinocmbryonic antigen (CEA). GI6207 is part of the GI-6200 series and means the single Tarmogen product that is the subject of [IND No. BB-IND 13934 (drug master file BB-MF 13884)], and that solely expresses human CEA having a N6lOD mutation.

GI-6l00 means the series of Tarmogen products that express human MUC- I antigen(s). GI-6108 is part of the GI-6l00 series and is the single Tarmogen product that is the current lead product for the GI-6100 program. GI-6108 is currently undergoing preclinical development at the National Institutes of Health under the terms of the CRADA.  As of the Amendment #5 Effective Date, GI-6l08 is believed to be the specific product intended to be subject of [an IND to be filed by the NIH under the CRADA. Should a different Tarmogen product expressing MUC-1 antigen(s), other than GI-6108, be selected for said IND], then it is understood such product shall become the Drug Candidate associated with the GI-6100 designation.

Gl-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that is the subject of [BB-IND 14895].

Field of Use
The focus of the compound in this agreement is for the treatment of cancer.
GI-4000 series target tumors with mutations in a protein called Ras.

IPSCIO Record ID: 263773

License Grant
Licensor hereby grants to Licensee and its Affiliates the exclusive license, with the right to grant sublicenses solely under the Licensed Intellectual Property, to use, sell, offer to sell, import, make and have made and otherwise Develop, Commercialize or manufacture any Licensee Development Compound and any Licensed Product containing any such Licensee Development Compound, during the Term, in the Territory in the Field, such license to be effective upon Licensee’s exercise of a Licensee Program Option for the Collaboration Compound corresponding to such Licensee Development Compound in accordance with the terms of this Agreement.

This agreement is a worldwide strategic collaboration focused on the discovery, development and commercialization of multiple product candidates based on powerful, targeted molecular immunotherapy.

For the Licensed Intellectual Property, Licensor grants the exclusive, even as to Licensor and its Affiliates, worldwide, nontransferable license, with the right to grant sublicenses, under the Licensed Intellectual Property, to use, sell, offer to sell, import, make and have made, and otherwise Develop, Commercialize or manufacture any Licensee Development Compound and any Licensed Product containing any such Licensee Development Compound, during the Term, in the Territory in the Field, such license to be effective upon Licensees exercise of a Licensee Program Option for the Collaboration Compound corresponding to such Licensee Development Compound.

For Licensees Program Option, Licensor grants the exclusive right, exercisable at Licensees sole discretion, to elect, with respect to any Program, on a Program-by-Program basis, to obtain an exclusive worldwide license to Develop, Commercialize, and manufacture the applicable Licensee Development Compound, and any Follow-On Compound with respect to such Licensee Development Compounds within such Program as Licensed Products under the terms and conditions set forth in this Agreement.

For the Trademarks for Licensed Products, Licensor grants an exclusive right and license, with the right to grant sublicenses, to Trademarks Controlled by Licensor solely for use with respect to such Licensed Product.

Licensee and its Affiliates shall have the right to grant sublicenses.

License Property
A Drug Candidate means GI-4000, GI-6200, GI-3000, or GI-10000.

GI-4000 is a Tarmogen technology-based product currently in phase II pancreatic cancer studies.   Tarmogens are proprietary therapeutic product candidates designed to stimulate the immune system to recognize and eliminate diseased cells from the body.   Tarmogens are whole, heatkilled recombinant S. cerevisiae yeast that express antigens from one or more disease-related proteins. GI-4000, the lead oncology program under this collaboration, is a series of Tarmogens that are intended to generate a T cell immune response against cells containing proteins encoded by a mutated ras oncogene.

GI-6200 means the series of Tarmogen products that solely express human carcinoembryonic antigen (CEA). GI-6207 is part of the GI-6200 series and means the single Tarmogen product that is the subject of [IND No. BB-IND 13934 (drug master file BB-MF 13884)], and that solely expresses human CEA having a N610D mutation.

GI-3000 means the series of Tarmogen products that solely express human epidermal growth factor receptor (EGFR). GI-3010 is part of the GI-3000 series and means the single Tarmogen product that is the subject of [a pre-IND package dated March 16, 2006], and that solely expresses human EGFR lacking the secretory signal sequence and the transmembrane domain.

GI-10000 means the series of Tarrnogen products that express Ber-Ab! and/or one or more peptides thereof. GI-10000 includes Tannogen products expressing Bcr-Abl or peptides thereof that contain the Ber-Ab] junctional region, including the specific Tarmogen products GI-l 0003, GI-10007, GI-10008 and GI-10009. GI-10000 also includes Tarmogen products expressing BcrAbl or peptides thereof that contain one or more escape mutations resulting from targeted therapy, such as E255K, T3 I 5I, and M35 IT]. Specific Tarmogen products containing {escape mutations in the Abl kinase are denoted GI-10001, GI-10002, GI-10004, GI-10005 and Gl10006.

The Licensed Product means any product in final form that contains a Licensee Development Compound as a therapeutically active ingredient.

A Compound as used herein includes a biologic and a pharmaceutical compound.

Field of Use
The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 263928

License Grant
With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.
License Property
GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.
Field of Use
The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

IPSCIO Record ID: 110461

License Grant
The University grants to Licensee and its Affiliates the exclusive license in the Territory with the right to grant sublicenses to others, under the Patent Rights, to make, have made, use, sell, import and offer for sale Products and to practice Processes.

Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.

License Property
The licensed patent applications relate to a Modified Heat Shock Protein-Antigenic Peptide Complex.
Field of Use
The licensed patent is in the area of the use of heat shock proteins for the development of therapeutic and prophylactic vaccines for cancer and infectious diseases (the 'Field').

IPSCIO Record ID: 279292

License Grant
For the Licensed Intellectual Property, Licensor grants the exclusive, even as to Licensor, a worldwide, nontransferable right and license, with the right to grant sublicenses, under the Licensed Intellectual Property, to use, have used, sell, have sold, offer to sell, import, have imported, make and have made, and otherwise research, Develop, Commercialize or manufacture any Licensed Vaccine and/or Licensed Product, during the Term, in the Territory in the Field.

For the Trademarks for Licensed Products. To the extent that Licensor owns any Trademark(s) that pertain specifically to a Licensed Vaccine or Licensed Product, Licensor grants an exclusive right and license, with the right to grant sublicenses to Trademark(s) Controlled by Licensor solely for use with respect to such Licensed Vaccine or Licensed Product, as the case may be.

License Property
Licensor has expertise in drug discovery, development, and manufacturing of yeast-based immunotherapeutics known as Tarmogen® products.

Licensor has rights under certain patent rights and know-how rights relating to Tarmogens.

Licensed Product means any product in final form that contains a Licensed Vaccine as a therapeutically or prophylactically active ingredient.

Combination Product means any product sold in a particular country that contains a Licensed Vaccine in combination with one (1) or more other therapeutically active ingredients or drug delivery technology, devices, equipment or other components, as applicable, or formulated or packaged separately but sold together for a single price.

Field of Use
The collaboration is for the prevention and/or treatment of hepatitis B virus infection and its sequelae.  The goal of the research collaboration is to create and develop therapeutic vaccine products that have specific HBV DNA antigens cloned into S. cerevisiae (a species of yeast).

The Field means, any and all human diseases and conditions, except the treatment of any malignancy; provided, however, that Field shall include [the treatment, palliation, diagnosis and/or prevention of hepatitis that may result in the prevention and/or reduction in frequency and incidence of any and all sequelae of hepatitis infection, including the prevention and/or reduction in the frequency and incidence of hepatocellular carcinoma in patients who have co-existing hepatocellular carcinoma.

IPSCIO Record ID: 362483

License Grant
Licensors, as applicable, grant to Licensee of Switzerland an exclusive, sub-licensable license, under the Licensor IP in the Territory in the Field,
–  to generate and test Chimeric Antigen Receptor T-Cell Products solely for the Development, Regulatory Approval and Commercialization of Products containing such Chimeric Antigen Receptor I-Cell Products;
–  to Develop and Commercialize Products in the Field in the Territory, provided that such Products are not Out-of-Scope Products; and
–  to Commercialize the Chimeric Antigen Receptor for Products.
License Property
Licensor has expertise in and owns or controls proprietary technology relating to genetically engineering cells to target and destroy cancer cells.

Product means any pharmaceutical product containing a Chimeric Antigen Receptor I-Cell Product developed by Licensor under a Research Program for which the JSC determines to file an IND or under a research program for which Licensee has exercised the Licensor Program Option, or, any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by or on behalf of Licensee that is a derivative of or is otherwise developed from or based upon a Chimeric Antigen Receptor T-Cell Product described above.

Allogcneic Cell Therapy means a genomically engineered patient-nonspecific T-cell expressing a Chimeric Antigen Receptor for delivery to a patient developed under the Allogeneic Cell Therapy Research Program satisfying the Allogeneic Cell Therapy Criteria.

Chimeric Antigen Receptor T-Cell Product means a T-Cell having a Chimeric Antigen Receptor, or, a T-cell under switch control having a Chimeric Antigen Receptor and any Activator Ligands or Exclusive Activator Ligands that are administered to control such T-cells irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such T-cell directed to a Target, or, an Allogeneic Cell Therapy, or, the Allogeneic Cell Therapy under switch control having a Chimeric Antigen Receptor directed to a Target and any Activator Ligands or Exclusive Activator Ligands that are administered to control such Allogeneic Cell Therapy irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such Allogeneic Cell Therapy, or, any component sold as a kit, such as a device, delivery system or therapy scheme for the above to modify such T-cell including one or more polypeptides or nucleic acids encoding a CAR.

Licensor Platform Technology means Licensors platform of research tools and technology necessary for Licensor to perform its tasks directed towards the design, identification, culturing, and/or production of genetically modified cells consistent with this Agreement, including without limitation the technology embodied in the Licensor Materials and the Licensor Patents, and specifically including without limitation the following of Licensors platform areas and capabilities
(I) UltraVcctor,
(2) LEAP,
(3) DNA and RNA MOD engineering,
(4) protein engineering,
(5) transcription control chemistry,
(6) genome engineering,
(7) cell system engineering,
(8) Endometrial Regenerative Cells,
(9) the RheoSwitchE technology and RheoSwitch Therapeutic Systems, and
(10) MD Anderson CC Technologies.

Field of Use
The Field means the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.